RPTX posts RP-1664 Phase 1 LIONS abstract ahead of AACR-NCI-EORTC

Rhea-AI Filing Summary

Repare Therapeutics reported a Regulation FD update announcing that the abstract from its Phase 1 LIONS trial of RP-1664 has been made available. The preliminary data in the abstract will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The abstract, titled “Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification,” is posted on the Company’s website under Science > Scientific References.

The Company noted that information on its website is not incorporated by reference into other filings unless specifically stated.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Understanding 8-K Material Events →

0001808158false00-000000000018081582025-10-222025-10-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2025

Repare Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

Quebec			001-39335	Not applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
7171 Frederick-Banting, Building 2 Suite 270
St-Laurent, Quebec, Canada				H4S 1Z9
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 412-7018

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common shares, no par value		RPTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 22, 2025, Repare Therapeutics Inc. (the "Company") announced that the abstract related to the Company’s Phase 1 LIONS trial of RP-1664 was made available. The preliminary data in the abstract will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The abstract is available under the “Scientific References” tab of the “Science” section of the Company’s website under the title “Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification.”

The information contained herein is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

The Company’s website and any information contained on the Company’s website are not incorporated into this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			REPARE THERAPEUTICS INC.
Date:	October 22, 2025	By:	/s/ Steve Forte
			Steve Forte President, Chief Executive Officer and Chief Financial Officer

FAQ

What did RPTX announce in this 8-K?

The Company announced that the abstract for its Phase 1 LIONS trial of RP-1664 is available and will be presented at the 37th AACR-NCI-EORTC conference.

What is RP-1664 according to Repare Therapeutics?

RP-1664 is described as a first-in-class PLK4 inhibitor evaluated as monotherapy in advanced solid tumors with and without TRIM37 amplification.

Where can investors find the RP-1664 abstract on RPTX’s site?

It is available under the “Scientific References” tab of the “Science” section on the Company’s website.

When and where will the data be presented?

The preliminary data will be presented at the 37th AACR-NCI-EORTC conference in Boston, Massachusetts.

Does this announcement change RPTX’s SEC filings by incorporation?

No. The Company stated its website information is not incorporated by reference into other filings unless expressly referenced.

Does the 8-K disclose financial terms or transactions?

No. It is a Regulation FD disclosure about the availability and presentation of a scientific abstract.